MktsMarkets

Edesa Biotech, Inc.
NASDAQ: EDSAKey statistics
EDSA News
Stories mentioning EDSA from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 2,767 | 1,125 | 1,226 | 939.00 | 484.00 | 1,020 | 105.00 | 897.00 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | ||||||||
| Operating Income (Loss) | (4,297) | (2,341) | (2,470) | (1,904) | (1,639) | (1,899) | (1,006) | (1,932) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | (4,218) | (1,749) | (1,590) | (1,668) | ||||
| Tax Provision | 1.00 | 0.00 | 1.00 | 0.00 | ||||
| Net Income (Loss) | (4,218) | (2,248) | (2,230) | (1,749) | (1,590) | (1,617) | (963.00) | (1,668) |
| Earnings Per Share (Basic) | (0.49) | (0.28) | (0.39) | (0.25) | (0.30) | (0.48) | (0.30) | (0.52) |
| Earnings Per Share (Diluted) | ||||||||
| Weighted Average Shares Outstanding (Basic) | 8,541 | 7,973 | 5,677 | 7,023 | 5,306 | 3,345 | 3,197 | 3,222 |
| Weighted Average Shares Outstanding (Diluted) | ||||||||
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About EDSA
Edesa Biotech, Inc. (NASDAQ: EDSA) is a stock listed on the Nasdaq Stock Market under the ticker symbol EDSA. It last traded at $2.06 (Nov 18, 2026, 4:00 PM ET), up 5.1% on the day. That gives Edesa Biotech a market capitalisation of $27.3M.
Over the past 52 weeks EDSA has traded between $0.7200 and $20.32.
For the quarter ended Mar 31, 2026 it reported a net loss of $4.2M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$4.2M |
| Dec 31, 2025 | — | -$2.2M |
| Sep 30, 2025 | — | -$2.2M |
| Jun 30, 2025 | — | -$1.7M |
From Edesa Biotech’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…